Published 2022
| Version v1
Publication
Reduction in Grey Matter Atrophy in Patients with Relapsing Multiple Sclerosis Following Treatment with Cladribine Tablets
Description
Measures of atrophy in the whole brain can reliably assess treatment effect in clinical trials of patients with multiple sclerosis (MS). Trials assessing the effect of treatment on grey matter (GM) and white matter (WM) atrophy are very informative, but hindered by technical limitations. This study used a robust longitudinal method to measure GM and WM volume changes in patients with relapsing MS randomized to cladribine tablets 3.5 mg/kg (CladT3.5) or placebo in the CLARITY study.
Additional details
Identifiers
- URL
- http://hdl.handle.net/11567/1098101
- URN
- urn:oai:iris.unige.it:11567/1098101
Origin repository
- Origin repository
- UNIGE